Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058145 | 0.85 | HCRTR1 (0.48) | ALDH1A1HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL3065365 | 0.84 | HCRTR1 (0.42) | TP53KDM4EHCRTR1HCRTR2CYP2C9 | |
| SCHEMBL1398919 | 0.84 | HCRTR1 (0.47) | TP53HCRTR1HCRTR2LMNA | |
| SCHEMBL1398834 | 0.84 | HCRTR1 (0.57) | HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL1398831 | 0.84 | HCRTR1 (0.57) | HCRTR1HCRTR2LMNATSHR | |
| SCHEMBL3058147 | 0.82 | MEN1 (0.48) | ALDH1A1HCRTR1HCRTR2LMNA | |
| SCHEMBL3063120 | 0.80 | ALDH1A1 (0.49) | TP53KDM4EALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL3058405 | 0.80 | HCRTR1 (0.55) | HCRTR1HCRTR2CYP3A4TSHR | |
| SCHEMBL3070988 | 0.77 | HTT (0.52) | KDM4EALDH1A1CYP2C9CYP2C19HTT | |
| SCHEMBL3063297 | 0.77 | HCRTR2 (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | TP53 4881/4885KDM4E 903/4885ALDH1A1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.